The Enterprise Value as of November 2024 (TTM) for BeiGene, Ltd. (BGNE) is 19.75B

According to BeiGene, Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 19.75B. This represents a change of 9.33% compared to the average of 18.06B of the last 4 quarters.

BeiGene, Ltd. (BGNE) Historical Enterprise Value (quarterly & annually)

How has BGNE Enterprise Value performed in the past?

The mean historical Enterprise Value of BeiGene, Ltd. over the last ten years is 10.33B. The current 19.75B Enterprise Value has changed 19.02% with respect to the historical average. Over the past ten years (40 quarters), BGNE's Enterprise Value was at its highest in in the September 2021 quarter at 32.99B. The Enterprise Value was at its lowest in in the March 2016 quarter at 460.66M.

BeiGene, Ltd. (BGNE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BeiGene, Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BeiGene, Ltd. (BGNE) Average Enterprise Value

How has BGNE Enterprise Value performed in the past?

The current Enterprise Value of BeiGene, Ltd. (BGNE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BeiGene, Ltd. (BGNE) Enterprise Value vs. Peers

How is BGNE’s Enterprise Value compared to its peers?

BeiGene, Ltd.’s Enterprise Value is greater than Ascendis Pharma A/S (7.61B), greater than Apellis Pharmaceuticals, Inc. (3.90B), greater than Akero Therapeutics, Inc. (2.00B), greater than Blueprint Medicines Corporation (6.36B), greater than I-Mab (448.84M), greater than Krystal Biotech, Inc. (5.10B), greater than Immunovant, Inc. (3.47B), greater than Mirati Therapeutics, Inc. (3.91B), greater than Incyte Corporation (12.55B), greater than BioMarin Pharmaceutical Inc. (12.17B), greater than ImmunoGen, Inc. (8.19B), greater than Prometheus Biosciences, Inc. (9.30B), greater than Arrowhead Pharmaceuticals, Inc. (2.69B), greater than Ionis Pharmaceuticals, Inc. (6.48B), greater than Legend Biotech Corporation (7.40B), greater than Vaxcyte, Inc. (10.01B), greater than Travere Therapeutics, Inc. (1.95B),

Build a custom stock screener for BeiGene, Ltd. (BGNE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeiGene, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeiGene, Ltd. (BGNE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeiGene, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.